Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Real Estate Group Represents One Wall Partners in a $63 Million, 16-Building, Portfolio Acquisition - September 20, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar & Co., LLC in $10 Million Public Offering of American Depository Shares of BiondVax Pharmaceuticals Ltd. (Israel) - September 19, 2017
- Los Angeles Times Interviews Gregory Sichenzia on Google’s Potential Investment in Lyft - September 17, 2017